BioCentury
ARTICLE | Finance

Ducks in a row

Preclinical microRNA play Regulus files IPO; partners with Biogen, AstraZeneca

August 20, 2012 7:00 AM UTC

microRNA play Regulus Therapeutics Inc. is hoping Verastem Inc. (NASDAQ:VSTM) didn't satiate investor appetite for preclinical biotech plays.

Last week, Regulus filed to raise up to $57.5 million in an IPO, becoming the first preclinical company to do so since cancer stem cell play Verastem went public in January. The filing capped a week in which Regulus announced deals with Biogen Idec Inc. (NASDAQ:BIIB) and AstraZeneca plc (LSE:AZN; NYSE:AZN)...